Meta to Ignore Ethics Board’s Advice on Drug-Post Oversight
- Board found ‘inconsistent enforcement’ of drug-related posts
- Instagram, Facebook owner may consider a review in 2024
This article is for subscribers only.
Meta Platforms Inc., the owner of Facebook and Instagram, will ignore some of its ethics watchdog’s advice to tighten up its oversight of drug-related posts, in a decision with widespread ramifications for how people learn about psychedelic drugs.
The Oversight Board’s guidance on drugs stems from a 2022 post tagged to a “paid partner” that described a ketamine treatment as a “medicine” and a “magical entry into another dimension.” Meta removed and reinstated the post three times.